You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Claims for Patent: 5,166,207

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,166,207

Title:	Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders
Abstract:	A method for enhancing the systemic delivery of dextromethorphan for the treatment of a neurological disorder resulting in injury to nervous tissue, which comprises administering to a patient suffering from the disorder an amount of a cytochrome P450IID6 enzyme inhibitor, sufficient to block dextromethorphan metabolism, and an amount of dextromethorphan sufficient to treat the neurological disorder. Quinidine is particularly suitable for use in the method of the invention.
Inventor(s):	Smith; Richard A. (La Jolla, CA)
Assignee:	NeuroTherapeutics, Inc. (San Diego, CA)
Application Number:	07/717,424
Patent Claims:	1. A method for enhancing the systemic delivery of dextromethorphan for the treatment of a neurological disorder resulting in injury to nervous tissue, which comprises: administering to a patient suffering from said neurological disorder an amount of a cytochrome P450IID6 enzyme inhibitor, sufficient to block dextromethorphan metabolism, and an amount of dextromethorphan, sufficient to treat said neurological disorder. 2. The method of claim 1, wherein said inhibitor is quinidine. 3. The method of claim 1, wherein said neurological disorder results from ischemia, hypoxia, hypoglycemia, epilepsy, Huntington's disease, Alzheimer's disease, or amyotrophic lateral sclerosis. 4. A method for enhancing the systemic delivery of dextromethorphan for the treatment of a neurological disorder mediated by an endogenous excitatory amino acid, which comprises: administering to a patient suffering from said neurological disorder an amount of a cytochrome P450IID6 enzyme inhibitor, sufficient to block dextromethorphan metabolism, and an amount of dextromethorphan, sufficient to treat said neurological disorder. 5. The method of claim 4, wherein said inhibitor is quinidine. 6. The method of claim 4, wherein said neurological disorder results from ischemia, hypoxia, hypoglycemia, epilepsy, Huntington's disease, Alzheimer's disease, or amyotrophic lateral sclerosis.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.